[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Seven cases with pulmonary metastases from the urogenital tract were treated with VP-16 in either oral doses of 200 mg or intravenous doses of 100 mg for 5 days. Two of 4 cases with transitional cell cancer from the urinary bladder and a case with prostatic adenocarcinoma responded to the treatment. Another 2 cases with adenocarcinoma arising from the kidney showed no response. Leucopenia, thrombocytopenia and alopecia were outstanding side effect.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000284:Administration, Oral; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000556:secondary; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D007680:Kidney Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014571:Urologic Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D011034:Podophyllotoxin